Although in cold mucosal biopsies, the risk of clinically significant bleeding is estimated to be less than 0.5% (26), patients with EGID may exhibit increased mucosal fragility promoted by the release of eosinophilic cytotoxic granular proteins such as major basic protein, eosinophil cationic protein, eosinophil peroxidase, and eosinophil derived neurotoxin (27). Here, EPX is linked to eosinophilic gastrointestinal disease.